Fabrazyme® (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.

The global Fabrazyme (agalsidase beta) market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Fabrazyme (agalsidase beta) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Fabrazyme (agalsidase beta) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Genzyme Corporation
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
5mg/vial
35mg/vial

Segment by Application
Hospital
Drug store